Literature DB >> 8632672

Tissue factor expression in human leukemic cells.

G A Hair1, S Padula, R Zeff, M Schmeizl, J Contrino, D L Kreutzer, P de Moerloose, A W Boyd, I Stanley, A W Burgess, F R Rickles.   

Abstract

Patients with acute leukemia are at increased risk for thrombotic and hemorrhagic complications, particularly those patients with acute promyelocytic leukemia (APL) undergoing induction chemotherapy. These serious complications have been attributed by some authors to the release of tissue factor (TF) procoagulant activity (PCA), particularly during cytotoxic chemotherapy. In previous studies of normal peripheral blood cells, only cells of the monocyte lineage have been found to express TF PCA. Therefore, several questions remain regarding the origin and characterization of the PCA in malignant leukemic cells, particularly those thought to be derived from granulocyte progenitor cells. We utilized a full-length cDNA probe, several monoclonal antibodies (MAbs) and a sensitive one-stage PCA assay to study the expression of TF in the human cell line, HL-60, in human peripheral blood monocytes/macrophages (Mo/Mø) and in highly purified populations of human polymorphonuclear leukocytes (PMN). In the HL-60 cells we detected low but significant levels of TF mRNA and TF antigen (TF:Ag). In unstimulated cells, coordinate increased levels of TF mRNA, TF:Ag and TF PCA expression were noted following phorbol-ester-induced macrophage differentiation of the cells, but a decreased level of TF mRNA with no change in the basal level of TF:Ag expression occurred following retinoic acid-induced granulocyte differentiation of this cell line. Long-term cultures of stimulated mature Mo/Mø demonstrated initial coordinate expression of TF mRNA, TF:Ag and TF PCA, but TF:Ag expression persisted even after 7 days (when TF PCA was undetectable). No TF PCA, TF:Ag or TF mRNA was demonstrated in highly purified populations of human PMN, regardless of culture conditions. Discordant expression of TF mRNA, TF:Ag and TF PCA in HL-60 cells suggests the possibility of novel, post-synthetic mechanisms for the regulation of TF PCA expression, which might be dependent on the phenotypic differentiation level of the cell. Such mechanisms (yet to be defined) might account for the ability of some leukemic cells, which frequently express characteristics of more than one cell line (e.g. monocytes and granulocytes), to express a TF gene product capable of activating blood coagulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632672     DOI: 10.1016/0145-2126(95)00107-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.

Authors:  M Shoji; W W Hancock; K Abe; C Micko; K A Casper; R M Baine; J N Wilcox; I Danave; D L Dillehay; E Matthews; J Contrino; J H Morrissey; S Gordon; T S Edgington; B Kudryk; D L Kreutzer; F R Rickles
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

2.  Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.

Authors:  Qing Zhang; Xiujun Liu; Shuangshuang Xu; Caihong Li; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  Cancer Biother Radiopharm       Date:  2012-05-31       Impact factor: 3.099

3.  Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.

Authors:  Zhiwei Hu; Benqiang Rao; Shimin Chen; Jinzhong Duanmu
Journal:  Breast Cancer Res Treat       Date:  2010-06-01       Impact factor: 4.872

4.  Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.

Authors:  Zhiwei Hu; Benqiang Rao; Shimin Chen; Jinzhong Duanmu
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

5.  Immuno-PET of tissue factor in pancreatic cancer.

Authors:  Hao Hong; Yin Zhang; Tapas R Nayak; Jonathan W Engle; Hing C Wong; Bai Liu; Todd E Barnhart; Weibo Cai
Journal:  J Nucl Med       Date:  2012-09-17       Impact factor: 10.057

6.  Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.

Authors:  J Duanmu; J Cheng; J Xu; C J Booth; Z Hu
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

7.  Tissue factor, blood coagulation, and beyond: an overview.

Authors:  Arthur J Chu
Journal:  Int J Inflam       Date:  2011-09-20

8.  Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Authors:  Anna Falanga; Laura Russo; Carmen J Tartari
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

9.  Changes in the Laboratory Data for Cancer Patients Treated with Korean-medicine-based Inpatient Care.

Authors:  Jeungwon Yoon; Chong-Kwan Cho; Ji-Eun Shin; Hwa-Seung Yoo
Journal:  J Pharmacopuncture       Date:  2014-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.